Biophan to Exhibit at Medical Design Meeting; Company to Highlight Advanced Technologies for MRI Safety to Medical Device Designers and Manufacturers.

ROCHESTER, N.Y. -- Biophan Technologies, Inc. (OTCBB: BIPH), a developer of next-generation biomedical technology, today announced that it will be attending and exhibiting at the Medical Design and Manufacturing show, MD&M West, at the Anaheim Convention Center in Anaheim, California on January 10 through 12, 2005.

Biophan will highlight advanced technologies at the show, including the MRI-safe ceramic motor, designed for devices such as implantable drug pumps, as well as Biophan's technologies for enabling virtually any interventional device or implant to be made MRI-safe and compatible. Biophan's patented anti-antenna technology to enable device safety will also be featured at the show.

Biophan will be demonstrating its patented and patent pending, ready-to-ship solutions:

--MRI safe lead solutions for pacemakers, defibrillators, spinal pain devices, neurostimulators, and other implanted medical devices (both the Johns Hopkins patented RF filter and the Biophan patented anti-antenna solutions) http://www.biophan.com/shielding.php

--MRI imaging solutions for stents, guidewires, medical devices, including prosthetic devices (using both Nanoset's thin film nanomagnetic particle coatings, licensed exclusively to Biophan, and Biophan's anti-antenna solutions). http://www.biophan.com/pr/080904NanosetWebsite_and_print.html

--The MRI safe Squiggle Motor--Biophan holds the worldwide distribution rights to New Scales' MRI Safe Squiggle motor for all medical applications. New Scale's CEO Dave Henderson, and New Scale staff members, will be at the Biophan booth exhibiting the Squiggle motor). http://www.biophan.com/ceramicpic.php and http://www.biophan.com/ceramicvideo.php

Biophan will also demonstrate its technologies in development:

--MRI contrast agents for improved MRI imaging-- http://www.biophan.com/contrastPage.php

--Biothermal battery, being developed with NASA to power implantable medical devices with body heat, vs. chemical batteries, as well as to recharge chemical batteries in devices such as defibrillators-- http://www.biophan.com/biothermalPage.php

The conference, organized by Canon Communications, LLC, is one of the largest meetings for medical device designers and manufacturers, and will be attended by thousands of key designers and medical device executives from the United States, Europe and Asia. For further information on the conference, please visit www.mdmwest.com.

"We're looking forward to highlighting the latest achievements from Biophan in the development of our nanotechnology-based biomedical device solutions," said Michael Weiner, CEO of Biophan. "Biophan is at the forefront of the next generation of biomedical devices, and our proprietary technologies advance the safety and efficacy of MRI across a wide spectrum of diagnostic and surgical procedures. Now that we have developed and patented the key solutions, we are aggressively expanding our marketing efforts and increasing industry presence. This show is the kick-off for these new marketing initiatives and complements the transactions we anticipate closing in the first quarter of 2005."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 103 U.S. patents, licenses or applications. This total includes 25 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 70 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.